AUSTIN, Texas & OKLAHOMA CITY--(BUSINESS WIRE)--Caisson Biotech, LLC (Caisson), a leader in half-life extension and drug delivery, today announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma), a full-service Contract Development & Manufacturing Organization (CDMO) manufacturing APIs and Drug Products through a network of cGMP facilities across Europe and the US.
Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners utilizing its patented heparosan-based half-life extension and drug delivery platform, HEPtune®, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material. As a manufacturer of the HEPtune® technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates, which are an integral component of its Peptides, Lipids & Carbohydrates technology platform offering.
“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, PhD, Vice President and Managing Director of Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”
Mimoun Ayoub, PhD, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CordenPharma International, said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s Peptides, Lipids & Carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”
About Caisson Biotech
Caisson Biotech, LLC is a privately held biopharmaceutical company that actively out-licenses its HEPtune proprietary drug delivery platform for use with active pharmaceutical ingredients, including proteins, peptides, small molecules and liposomal delivery systems. Heparosan conjugation has been developed by Caisson and includes a robust U.S. and international patent portfolio enabling its clients to create new composition of matter patents by leveraging the patent protected drug delivery system. Visit: www.caissonbiotech.com
Caisson is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.emergenttechnologies.com
CordenPharma International, a pharmaceutical brand of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics - CordenPharma experts translate complex ideas at any stage of development into high-value products. Visit: www.cordenpharma.com